Compare CTKB & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | BDN |
|---|---|---|
| Founded | 1990 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.1M | 588.8M |
| IPO Year | 2021 | N/A |
| Metric | CTKB | BDN |
|---|---|---|
| Price | $4.17 | $3.03 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $5.70 | $4.00 |
| AVG Volume (30 Days) | 890.3K | ★ 3.0M |
| Earning Date | 02-25-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 10.42% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $196,828,000.00 | ★ $426,773,000.00 |
| Revenue This Year | $0.15 | $18.25 |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.92 |
| 52 Week Low | $2.37 | $2.74 |
| 52 Week High | $6.18 | $5.09 |
| Indicator | CTKB | BDN |
|---|---|---|
| Relative Strength Index (RSI) | 27.05 | 48.64 |
| Support Level | $4.86 | $2.74 |
| Resistance Level | $5.29 | $3.28 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 6.22 | 48.25 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.